Catalyst Pharm Inc (CPRX)

$17.27 0.64 (3.85%)

16:00 EST CPRX Stock Quote Delayed 30 Minutes

The 7 Best Stocks to Buy on a Dip

By Larry Ramer, InvestorPlace Contributor Nov 29, 2022

The best stocks to buy on a dip can come in many forms, but these seven names look set to deliver outsized returns on a reversal.

7 of the Top-Rated Pharmaceutical Stocks for Q1

3 Low-Priced Stocks That Make Smart Bets

7 Penny Stocks That Wall Street Thinks Are Undervalued

More Articles

Volume:

Previous Close -

Market Cap 1.78B

PE Ratio 143.92

EPS 0.12

Volume (Avg. Vol.) 3.38M

Day's Range $16.51 - $17.55

52-Week Range $5.24 - $18.39

Dividend & Yield N/A (N/A)

CPRX Stock Predictions, Articles, and Catalyst Pharm Inc News

From InvestorPlace
From the Web

7 Penny Stock Companies That Actually Make Money

By Mark Putrino, CMT Feb 19, 2021

Penny stocks are low price for a reason. Most presume they're destined for bankruptcy. But these seven may survive: they actually make money.

Despite Legal Drama, Catalyst Pharmaceuticals Looks Oversold

By Chris Markoch, InvestorPlace Contributor Nov 3, 2020

Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk.

Why Catalyst Pharmaceuticals Stock Is Feeling the ‘Bern’

By Josh Enomoto, InvestorPlace Contributor Oct 20, 2020

Typically, a major clinical victory would boost names like Catalyst Pharmaceuticals stock. Unfortunately, some political rumblings and an unexpected competitor got in the way of CPRX.

9 Robinhood Stocks Flying Under the Radar

By Josh Enomoto, InvestorPlace Contributor Sep 14, 2020

Robinhood stocks have generated much attention this year, but here are some names that you may not have heard about.

4 Strong Buy Biotech Stocks With Upcoming FDA Decisions

By Harriet Lefton, Writer, TipRanks Oct 23, 2018

These biotech stocks have fast-approaching PDUFA dates. Biotechs can soar or plunge on FDA decisions. These four pharma stocks should soar.

26 Biotechnology Stocks to Sell Now

By Portfolio Grader Sep 19, 2016

The ratings of 26 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

23 Biotechnology Stocks to Sell Now

By Portfolio Grader Sep 12, 2016

The overall ratings of 23 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Stocks Celebrate GOP Win on Bipartisan Hopes

By Anthony Mirhaydari, InvestorPlace Market Strategist Nov 5, 2014

Now on the horizon: The ECB, payrolls and Friday's showdown between President Obama and congressional leaders.

5 Red-Hot Biotech Stocks to Buy

By Anthony Mirhaydari, InvestorPlace Market Strategist Oct 27, 2014

Investors have been chasing risk again, buying up biotech stocks. Here's our list of the best biotech stocks out there.

Follow Analyst Andrew Fein for a 100% Success Rate on Catalyst Pharma (NASDAQ:CPRX)

From TipRanks Nov 23, 2022

Analyst Andrew Fein of H.C. Wainwright has scored a 100% success rate on his views on Catalyst Pharmaceuticals (NASDAQ:CPRX) stock. Fein is an expert in tracking U....

CPRX stock hits 52-week high amid acquisition hopes (NASDAQ:CPRX)

From Seeking Alpha Nov 22, 2022

Catalyst Pharmaceuticals (CPRX) reached a new 52-week high on Tuesday to extend its YTD gain to more than 150% as Wall Street expects the small-cap biotech to announce an acquisition...

Catalyst Pharma (CPRX) Receives a Buy from H.C. Wainwright

From TipRanks Nov 11, 2022

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report), with a price target of $18.0...

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

From MarketBeat Nov 11, 2022

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

Can Mid-Cap Lantheus Continue its 2022 Outperformance?

From MarketBeat Oct 28, 2022

Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test.

H.C. Wainwright Reaffirms Their Buy Rating on Catalyst Pharma (CPRX)

From TipRanks Aug 11, 2022

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report), with a price target of $18.0...